196 related articles for article (PubMed ID: 1689219)
1. H19, a surface membrane molecule involved in T-cell activation, inhibits channel formation by human complement.
Whitlow MB; Iida K; Stefanova I; Bernard A; Nussenzweig V
Cell Immunol; 1990 Mar; 126(1):176-84. PubMed ID: 1689219
[TBL] [Abstract][Full Text] [Related]
2. The complement-inhibitory activity of CD59 resides in its capacity to block incorporation of C9 into membrane C5b-9.
Rollins SA; Sims PJ
J Immunol; 1990 May; 144(9):3478-83. PubMed ID: 1691760
[TBL] [Abstract][Full Text] [Related]
3. Regulatory control of the terminal complement proteins at the surface of human endothelial cells: neutralization of a C5b-9 inhibitor by antibody to CD59.
Hamilton KK; Ji Z; Rollins S; Stewart BH; Sims PJ
Blood; 1990 Dec; 76(12):2572-7. PubMed ID: 1702330
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of homologous complement by CD59 is mediated by a species-selective recognition conferred through binding to C8 within C5b-8 or C9 within C5b-9.
Rollins SA; Zhao J; Ninomiya H; Sims PJ
J Immunol; 1991 Apr; 146(7):2345-51. PubMed ID: 1706395
[TBL] [Abstract][Full Text] [Related]
5. Molecular basis of the enhanced susceptibility of the erythrocytes of paroxysmal nocturnal hemoglobinuria to hemolysis in acidified serum.
Wilcox LA; Ezzell JL; Bernshaw NJ; Parker CJ
Blood; 1991 Aug; 78(3):820-9. PubMed ID: 1713516
[TBL] [Abstract][Full Text] [Related]
6. The PIG-anchoring defect in NK lymphocytes of PNH patients.
Schubert J; Uciechowski P; Delany P; Tischler HJ; Kolanus W; Schmidt RE
Blood; 1990 Sep; 76(6):1181-7. PubMed ID: 1698101
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of the lytic action of cell-bound terminal complement components by human high density lipoproteins and apoproteins.
Rosenfeld SI; Packman CH; Leddy JP
J Clin Invest; 1983 Apr; 71(4):795-808. PubMed ID: 6403580
[TBL] [Abstract][Full Text] [Related]
8. A synthetic peptide from complement protein C9 binds to CD59 and enhances lysis of human erythrocytes by C5b-9.
Tomlinson S; Whitlow MB; Nussenzweig V
J Immunol; 1994 Feb; 152(4):1927-34. PubMed ID: 7509832
[TBL] [Abstract][Full Text] [Related]
9. Complement lysis of human erythrocytes. Differeing susceptibility of two types of paroxysmal nocturnal hemoglobinuria cells to C5b-9.
Packman CH; Rosenfeld SI; Jenkins DE; Thiem PA; Leddy JP
J Clin Invest; 1979 Aug; 64(2):428-33. PubMed ID: 457861
[TBL] [Abstract][Full Text] [Related]
10. CD59 blocks not only the insertion of C9 into MAC but inhibits ion channel formation by homologous C5b-8 as well as C5b-9.
Farkas I; Baranyi L; Ishikawa Y; Okada N; Bohata C; Budai D; Fukuda A; Imai M; Okada H
J Physiol; 2002 Mar; 539(Pt 2):537-45. PubMed ID: 11882685
[TBL] [Abstract][Full Text] [Related]
11. Human protectin (CD59), an 18,000-20,000 MW complement lysis restricting factor, inhibits C5b-8 catalysed insertion of C9 into lipid bilayers.
Meri S; Morgan BP; Davies A; Daniels RH; Olavesen MG; Waldmann H; Lachmann PJ
Immunology; 1990 Sep; 71(1):1-9. PubMed ID: 1698710
[TBL] [Abstract][Full Text] [Related]
12. [Paroxysmal nocturnal hemoglobinuria (PNH) deficiency of major complement-regulatory membrane proteins on erythrocytes].
Ninomiya H; Kobayashi T; Abe T
Rinsho Ketsueki; 1991 Jun; 32(6):612-7. PubMed ID: 1716325
[TBL] [Abstract][Full Text] [Related]
13. Induction of the paroxysmal nocturnal hemoglobinuria phenotype in normal human erythrocytes: effects of 2-aminoethylisothiouronium bromide on membrane proteins that regulate complement.
Ezzell JL; Wilcox LA; Bernshaw NJ; Parker CJ
Blood; 1991 Jun; 77(12):2764-73. PubMed ID: 1710519
[TBL] [Abstract][Full Text] [Related]
14. Complement-induced vesiculation and exposure of membrane prothrombinase sites in platelets of paroxysmal nocturnal hemoglobinuria.
Wiedmer T; Hall SE; Ortel TL; Kane WH; Rosse WF; Sims PJ
Blood; 1993 Aug; 82(4):1192-6. PubMed ID: 7688991
[TBL] [Abstract][Full Text] [Related]
15. Serum-resistant strains of Borrelia burgdorferi evade complement-mediated killing by expressing a CD59-like complement inhibitory molecule.
Pausa M; Pellis V; Cinco M; Giulianini PG; Presani G; Perticarari S; Murgia R; Tedesco F
J Immunol; 2003 Mar; 170(6):3214-22. PubMed ID: 12626580
[TBL] [Abstract][Full Text] [Related]
16. Transfer of prostasomal CD59 to CD59-deficient red blood cells results in protection against complement-mediated hemolysis.
Babiker AA; Ronquist G; Nilsson UR; Nilsson B
Am J Reprod Immunol; 2002 Mar; 47(3):183-92. PubMed ID: 12069204
[TBL] [Abstract][Full Text] [Related]
17. Enhanced reactive lysis of paroxysmal nocturnal hemoglobinuria erythrocytes by C5b-9 does not involve increased C7 binding or cell-bound C3b.
Rosenfeld SI; Jenkins DE; Leddy JP
J Immunol; 1985 Jan; 134(1):506-11. PubMed ID: 3964820
[TBL] [Abstract][Full Text] [Related]
18. Deficiency of the homologous restriction factor in paroxysmal nocturnal hemoglobinuria.
Zalman LS; Wood LM; Frank MM; Müller-Eberhard HJ
J Exp Med; 1987 Feb; 165(2):572-7. PubMed ID: 2434597
[TBL] [Abstract][Full Text] [Related]
19. Paroxysmal nocturnal hemoglobinuria. Enhanced stimulation of platelets by the terminal complement components is related to the lack of C8bp in the membrane.
Blaas P; Berger B; Weber S; Peter HH; Hänsch GM
J Immunol; 1988 May; 140(9):3045-51. PubMed ID: 3361126
[TBL] [Abstract][Full Text] [Related]
20. Aurin tricarboxylic acid protects against red blood cell hemolysis in patients with paroxysmal nocturnal hemoglobinemia.
Lee M; Narayanan S; McGeer EG; McGeer PL
PLoS One; 2014; 9(1):e87316. PubMed ID: 24489894
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
